As antineutrophil cytoplasmic antibody positive rapidly progressive glomerulonephritis (ANCA-RPGN) has a high risk of end stage renal failure and is a potentially life threatening disease, early aggressive therapy is recommended. However, aggressive immunosuppressive therapy may lead to immunodeficiency and subsequent mortality in the patients with this disease. Therefore, we need the index of immunodeficiency to cure the disease. To evaluate any risk factors, including therapies, on mortality in ANCA-RPGN, we conducted a retrospective investigation on patient survival in 32 patients with ANCA-RPGN by Kaplan-Meier analysis and the Cox regression model. Fourteen patients were treated with leucocytapheresis (LAP group) and the 18 patients were treated by steroid pulse therapy (steroid pulse group) as initial treatment. The patients were chosen for the different therapies at random. Two patients in the LAP group, and eight patients in the steroid pulse group had died within 6 months. The lymphocyte counts and CD4 cell counts after complete course of therapy were lower in the patients who died than in those who survived in the steroid pulse group. Patient survival was higher in the LAP group than in the steroid pulse group, but did not reach statistical significance. Multivariate Cox regression analysis showed that the factors influencing patient survival were initial serum creatinine, LAP therapy, CD4 cell counts, and lymphocytes at the end of treatment. Age, titer of MPO-ANCA, and percent of glomerular crescents were not found to have an effect on the patient survival. We recommend: that early diagnosis should be established, and immunosuppressive therapy may be done with monitoring of the lymphocyte and CD4 cell count.

Keywords:
Rapidly progressive glomerulonephritis, MPO-ANCA, Lymphocytapheresis, Steroid pulse therapy, HelperT cell, Cytotoxic T cell, Macrophage
1.
Schrier RW, Gottschalk CW: Diseases of the Kidney, ed 6. Boston, Little, Brown, 1988, vol II, pp 1619–1640.
2.
Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 1989;9:368–375.
3.
Kunis CL, Kiss B, Williams G, D’Agati V, Appel GB: Intravenous ‘pulse’ cyclophosphamide therapy of crescentic glomerulonephritis. Clin Nephrol 1992;37:1–7.
4.
Rondeau E, Kourilsky O, Peraldi MN, Alberti C, Kanfer A, Sraer JD: Methylprednisolone and cyclophosphamide pulse therapy in crescentic glomerulonephritis: Safety and effectiveness. Renal Failure 1993;15:495–501.
5.
Pantaleo G, Fauci AS: New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995;13:487–512.
6.
Hotta O, Taguma Y, Yusa N, Ooyama M: Analysis of mononuclear cells in urine using flow cytometry in glomerular diseases. Kidney Int 1994;46(suppl 47):117–121.
7.
Hotta O, Yusa N, Ooyama M, Taguma Y: Urinary macrophage counts and ratio to T lymphocytes: possible use in differential diagnosis and management of glomerular disease. J Clin Lab Anal 1996;10:205–208.
8.
Hotta O, Taguma Y, Ooyama M, Yusa N, Hagura H: Analysis of CD14+ cells and CD56+ cells in urine using flow cytometry: a useful tool for monitoring disease activity of IgA nephropathy. Clin Nephrol 1993;39:289–294.
9.
Furuta T, Hotta O, Yusa N, Horigome I, Chiba S, Taguma Y: Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a randomized comparison with steroid-pulse treatment. Lancet 1998:352:203–204.
10.
Fujita S: Lymphocytapheresis uzing leukocyte removal filter in rheumatoid arthritis – comparizon with double filtration plasmapheresis. Jpn J Clin Immun 1990;13(3):268–276.
11.
Jackson AL, Warner NL: Preparation and analysis by flow cytometry of peripheral blood leukocytes; in Rose NR, Friedman H, Fahey JL (eds): Manual of Clinical Laboratory. Immunology, Washington, DC, American Microbiology Assoc, 1986, vol 70, pp 226–235.
12.
Jindal KK: Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: Evidence-based recommendations. Kidney Int 1999;55(suppl 70):33–40.
13.
Fauci AS, Lane HC: Human immunodeficiency virus (HIV) disease: AIDS and related disorders; in Harrison’s Principles of Internal Medicine ed 14. New York, McGraw-Hill, 1994, pp 1791–1856.
14.
Kawamoto S, Kawamura T, Utusnomiya Y, Kawaguchi Y, Hosoya T: Analysis of risk factor for patients and renal survival in anti-myeloperoxidase antibody (MPO-ANCA) associated glomerulonephritis. Jpn J Nephrol 1999;41(7):719–725.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.